Cytokinetics Inc. (NASDAQ:CYTK) was up 3% during trading on Monday . The stock traded as high as $12.33 and last traded at $12.12, with a volume of 140,885 shares traded. The stock had previously closed at $11.77.

Several equities research analysts have recently commented on CYTK shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $24.00 target price on shares of Cytokinetics in a research report on Tuesday, July 12th. Needham & Company LLC raised their target price on shares of Cytokinetics from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. FBR & Co reaffirmed a “buy” rating and issued a $24.00 target price on shares of Cytokinetics in a research report on Tuesday, June 21st. Roth Capital reissued a “buy” rating and set a $22.00 price target on shares of Cytokinetics in a research report on Thursday, August 18th. Finally, JMP Securities reissued a “buy” rating and set a $17.00 price target on shares of Cytokinetics in a research report on Tuesday, August 2nd. Eight research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $18.13.

The firm’s 50 day moving average price is $10.94 and its 200-day moving average price is $8.49. The stock’s market capitalization is $484.38 million.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. Equities research analysts predict that Cytokinetics Inc. will post ($1.30) earnings per share for the current year.

An institutional investor recently bought a new position in Cytokinetics stock. Matarin Capital Management LLC acquired a new position in shares of Cytokinetics Inc. (NASDAQ:CYTK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 240,163 shares of the biopharmaceutical company’s stock, valued at approximately $2,512,000. Matarin Capital Management LLC owned 0.62% of Cytokinetics at the end of the most recent quarter.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.